Drug Discovery

Quorum has built an exciting and broad portfolio of active microbiome therapeutics through the real-world application of translational medicine. By viewing human health and disease through the lens of the human microbiome, the physician-founders undertook the development of microbiome therapeutics for clinical entities that are being re-interpreted as dysbiotic states. The Company physician-founders input clinical relevancy into the research and drug discovery process, deriving biotherapeutics from the inherently beneficial human microbiome and working from human target-organ studies. Combining their early recognition of the many potential clinical applications of the human microbiome with a translational medicine approach has resulted in Quorum’s discovery of several Probiomic™ therapeutics, currently under active development for the treatment of multiple clinical entities ranging from chronic skin inflammation to chronic inflammation of the upper respiratory and digestive tracts to systemic metabolic disorders.